Sunitinib in combination with capecitabine within its licensed indication for the treatment of advanced and/or metastatic breast cancer
| Status: |
Suspended |
| Expected date of issue: |
TBC |
| Referral date: |
March 2009 |
| Wave: |
19 |
| Process: |
STA |
| Notes:
Cancer reform strategy Batch 5
|
| Topic area:
|
NICE project team
| Executive Lead: |
TBC
|
| Technical Lead: |
TBC
|
| Communications manager: |
TBC
|
| Project manager: |
TBC
|
|
Evidence review group:
|
TBC |
Provisional schedule
| Closing date for invited submissions / evidence submission: |
TBC |
| 1st appraisal committee meeting: |
TBC |
| 2nd appraisal committee meeting |
TBC |
Consultees and commentators
Project history
| Date |
Update |
| 5 April 2010 |
The manufacturer of sunitinib has advised us that regulatory approval for this technology is not being sought at this time following the receipt of trial data. The Institute has therefore decided to remove this appraisal from its current work programme. As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes. If you have any comments or concerns please do not hesitate to contact the Project Manager for this appraisal, Cathryn Hall (020 7045 2240 or email: (cathryn.hall@nice.org.uk). |
| 23 September 2009 |
Please note that following on from advice received from the manufacturer, this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid November 2010. The deadline for submissions is expected in approximately early February 2011. |
|
Key documents
This page was last updated: 06 April 2010
